Miller-The ASAM Principles of Addiction Medicine, 7e

xxiv

Preface

of this section’s content to readers. Expansion into increas ingly important topics such as the rapidly evolving field of electronic drug delivery devices (Chapter 22), cannabinoids (Chapter 17), and hallucinogens and dissociatives (Chapters 18 and 19) have been incorporated, and the chapter on novel psychoactive substances has been enriched (Chapter 23). Section 3 is a new section devoted to epidemiology and prevention. Led by a new trio of editors, Deepa R. Camenga, MD, Babalola Faseru, MD, and Catalina Lopez-Quintero, PhD, the section features new content on primary, second ary and tertiary prevention (24, SB1) and five substantially updated chapters focused on prevention for different popula tions, harm reduction, and public policy to address military personnel. Section 4, Diagnosis, Assessment, and Early Intervention Treatment, led by Emily C. Williams, PhD and Lisa J. Merlo, PhD, features expanded material on screening and brief inter ventions in a variety of settings, laboratory testing, assess ment, and community-based prevention. Three new sidebars have been added: Hospital-Based Addiction Care (33 SB1), Prevention and Early Treatment in the Workplace Setting (33, SB2), and an often neglected topic of Health Care Professional Wellness After Patient Overdose Death (34, SB1). Wilson M. Compton, MD, Karran A. Phillips, MD, and Deborah S. Finnell, PhD, lead Section 5 on Overview of Ad diction Treatment. The section includes 4 new chapters: Race, Ethnicity, Gender, and Social Determinants of Health, Dispari ties, and Access to Care; Treatment Considerations for LGBTQ Patients; Reducing Inequities of Care Through Changes in Practice (Chapters 38, 42, and 49); and Delivery of Addiction Medicine Care via Video or Phone—the evolution of which was greatly influenced by the COVID-19 pandemic, which be gan and ended during the production of this textbook. Jon E. Grant, MD, and Sarah W. Yip, PhD, lead Section 6, devoted to Nonsubstance Addiction-Related Disorders and provide updates on Gambling Disorder, Compulsive Sexual Behaviors and the global concern for Disorders Associated With Technology and Social Media (Chapter 54). Section 7, Management of Intoxication and Withdrawal, is led by Adam J. Gordon, MD, Mike A. Incze, MD, and Ana Holtey, DO, provides updates on the critical safety and patient engagement topic of management of substance withdrawal. Section 8, Pharmacological Interventions and Other So matic Therapies, led by Amy J. Kennedy, MD, Smita Das, MD, and Maria Gabriela Garcia Vassallo, MD, includes discussion of FDA-approved pharmacotherapies, off-label uses of phar macotherapies, as well as complimentary and integrative in terventions for addiction-related disorders. Medical Director Stewardship of Opioid Treatment Programs (OTPs) is a newly added sidebar (62, SB1). The management and pharmacologic treatment chapters in these sections have all been fully updat ed to include the most current information. A novel chapter on neuromodulation has also been expanded. Antoine Douaihy, MD, and Eric L. Garland, PhD, lead Section 9 on Psychologically Based Interventions. The section incorporates the latest research on a wide variety of behavioral

therapies and adds two new chapters on motivational inter viewing and mindfulness-based treatments as well as updates on digital media as treatment platforms. Richard K. Ries, MD, leads Section 10 on Mutual Help: Twelve Step and Other Pro grams in Addiction Recovery and contributes a chapter on spirituality and recovery. Section 11 has new leadership, Paula Lum, MD, Anika Alvanzo, MD, and Darius A. Rastegar, MD, and includes the latest research about medical disorders and complications of addiction. Arranged by body systems, this section includes important updates relating to hepatitis C and HIV, as well as approaches to the pregnant patient. Section 12, led by Edward V. Nunes, MD, and R. Jeffrey Goldsmith, MD, includes updated chapters on co-occurring addiction and mood, anxiety, psychotic, personality, eating, and substance-induced disorders, as well as ADHD and PTSD. Section 13 retains leadership from William C. Becker, MD, and Martin D. Cheatle, PhD, to review the biopsychosocial in tersections between pain and addiction. Legal and regulatory issues in opioid prescribing are also addressed for the reader. Sarah M. Bagley, MD, Sion Kim Harris, MD, and J. Wesley Boyd, MD, lead Section 14 on Children and Adolescents. This section has been interwoven with content in other sections re lating to subject matter on addiction-related issues in children and adolescents. Relevant to today’s policymaking climate, the impact of cannabis legalization and cannabis used as treat ment on youth are presented (Sidebar to Chapter 116). Newly added is a chapter focusing on Biopsychosocial Determinants of Development of Addiction in Children and Adolescents, as well as a renewed focus on Treating SUD in justice involved youth (Sidebar to Chapter 116 and Chapters 118, respectively). Timothy K. Brennan, MD, Robert L. DuPont, MD, and Corinne L. Shea, MA, lead Section 15, “Ethical, Legal, and Lia bility Issues in Addiction Practice.” In addition to several chap ters on each of these topics, this section provides a chapter on Therapeutic Effectiveness of Cannabis and Cannabinoids for medical (including psychiatric) conditions, Legal and Ethical Considerations for Clinicians Recommending Cannabis Used as Treatment to patients (Sidebar to Chapter 126). Attention is also given to chapters on drug testing, the MRO, and court leveraged treatment as well as incarcerated populations. Martha “Marty” Wunsch, MD, provided her strength in addition medicine as one of the founding editors of Journal of Addiction Medicine . Dr. Wunsch reviewed and updated the Appendices as we moved from Principles of Addiction Medi cine sixth edition to the seventh edition.

As the first and only addiction textbook to fully embrace nonstigmatizing terminology throughout the entire textbook, this was an inspiring endeavor for which the editors and ASAM thank all of our contributors. We aim to retain and revitalize effective coverage of foundational issues in our field, while also constantly sharpening the blade relating to novel and emerging topics in addiction medicine. We hope you find this textbook useful in your education, research, policymak ing, and most importantly in the care of patients whom we all serve. Copyright © 2024 Wolters Kluwer, Inc. Unauthorized reproduction of the content is prohibited.